All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Do you see improved outcomes when adding magrolimab to azacitidine in MDS and AML treatment?

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the AML Hub was delighted to speak to Naval Daver, MD Anderson Cancer Center, Houston, US. We asked: Do you see improved outcomes when adding magrolimab to azacitidine in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) treatment?

In this video, Naval Daver describes patient characteristics, the safety and efficacy results from an ongoing trial. He also explains the rationale behind focusing on patients with TP53 mutations and describes the encouraging survival rates, duration of response and remission.

Do you see improved outcomes when adding magrolimab to azacitidine in MDS and AML treatment?